Proteomics Mass Spectrometry Patents

Proteomics / mass spectrometry patents cover MS-instrument innovations; sample-prep and dynamic-range innovations; affinity (non-MS) proteomics innovations; and single-molecule protein-sequencing, acquisition, and quantification innovations — with IP held by mass-spec instrument makers and next-generation proteomics companies (in a field measuring the PROTEINS in biological samples at scale — the functional molecules that genes encode). WHY PROTEOMICS: genes (DNA/RNA) are the blueprint, but PROTEINS do the work — and protein levels, modifications, and interactions reveal biology and disease that genomics misses; proteomics is essential for biomarkers and drug targets, but is much HARDER than genomics because proteins can't be amplified (no PCR equivalent) and span an enormous DYNAMIC RANGE (in blood, abundances vary ~10 orders of magnitude, hiding low-abundance proteins). MAJOR PROTEOMICS PATENT HOLDERS: THERMO FISHER: the dominant MS platform (ORBITRAP high-resolution mass spectrometers). BRUKER: timsTOF (ion-mobility MS). SCIEX/DANAHER, WATERS (MS instruments). OLINK: Proximity Extension Assay (PEA — antibody-DNA affinity proteomics). SOMALOGIC: SomaScan (aptamer affinity). SEER: Proteograph (nanoparticle PROTEIN CORONA to compress dynamic range). NAUTILUS, QUANTUM-SI (single-molecule next-gen protein SEQUENCING). MS instruments, sample prep/dynamic range, affinity proteomics, and single-molecule sequencing/acquisition are the core proteomics patent domains — and dynamic-range compression, affinity multiplexing, single-molecule protein sequencing, and DIA are the open whitespace.

Mass-spectrometry-instrument innovations; ion-mobility and acquisition innovations; sample-prep and enrichment innovations; and dynamic-range-compression innovations represent core proteomics patent domains — and the mass spectrometer's performance and (above all) seeing low-abundance proteins across an enormous dynamic range are the central challenges. MASS-SPECTROMETRY-INSTRUMENT PATENTS: the analyzer that measures protein/peptide masses — high-resolution ORBITRAP (Thermo), time-of-flight, quadrupole, and hybrid instruments — improving resolution, mass accuracy, SENSITIVITY (detecting less material), scan speed, and DEPTH (proteins identified per run); the instrument is core, high-value IP held mainly by the big vendors. ION-MOBILITY / ACQUISITION PATENTS: adding an extra separation/selectivity dimension — ION MOBILITY (timsTOF, Bruker — separating ions by shape/size before MS to boost depth/speed), and acquisition methods (see below); ion mobility is a key differentiating instrument advance. SAMPLE-PREP / ENRICHMENT PATENTS: preparing samples for MS — protein digestion, peptide enrichment, depletion of high-abundance proteins, and post-translational-modification (PTM) enrichment (phospho/glyco); sample prep strongly affects what's detected. DYNAMIC-RANGE-COMPRESSION PATENTS: the plasma proteome's ~10-order dynamic range hides low-abundance (often most interesting) proteins — methods to COMPRESS dynamic range and capture low-abundance proteins, notably Seer's engineered NANOPARTICLE 'protein corona' (different nanoparticles bind different proteins, flattening abundance); dynamic-range compression is a high-value, differentiating whitespace. High-sensitivity/deep MS instruments, ion mobility, and dynamic-range-compression sample prep (nanoparticle corona) are the highest-value MS-side IP because instrument depth/sensitivity and seeing low-abundance proteins determine proteomic coverage.

Affinity (non-MS) proteomics innovations; single-molecule protein-sequencing innovations; data-acquisition (DIA) and quantification innovations; and PTM and bioinformatics innovations represent additional proteomics patent domains — and the non-MS approaches (affinity, single-molecule) that sidestep MS limits, plus how data is acquired and quantified, are where much modern innovation lies. AFFINITY (NON-MS) PROTEOMICS PATENTS: measuring proteins with BINDERS instead of (or alongside) MS — Olink's PROXIMITY EXTENSION ASSAY (PEA — antibody pairs with DNA tags read out by sequencing/qPCR, highly multiplexed/specific) and SomaLogic's APTAMERS (SomaScan); affinity proteomics offers high multiplexing/sensitivity for targeted panels and is a major, distinct IP area (binder reagents + readout). SINGLE-MOLECULE PROTEIN-SEQUENCING PATENTS: 'next-generation protein sequencing' — counting/identifying INDIVIDUAL protein molecules (analogous to how NGS transformed DNA) via fluorescent amino-acid recognition (Quantum-Si), N-terminal degradation/recognition cycles, or nanopore protein sequencing (Nautilus uses affinity-probe binding patterns); single-molecule protein sequencing is a frontier, high-value emerging IP area. DATA-ACQUISITION / QUANTIFICATION PATENTS: how the MS collects data — DATA-INDEPENDENT ACQUISITION (DIA, more comprehensive/reproducible than data-dependent), and quantification methods (isobaric labeling TMT/iTRAQ, label-free, SILAC); acquisition/quantification methods are valuable software+method IP. PTM / BIOINFORMATICS PATENTS: detecting/quantifying post-translational modifications (phosphorylation, glycosylation) and the computational pipelines (peptide/protein identification, FDR, quantification) that interpret proteomic data. Affinity-proteomics binders/readout, single-molecule protein sequencing, and DIA/quantification are the highest-value modern proteomics IP because non-MS multiplexing, single-molecule counting, and robust acquisition/analysis define the field's competitive frontier.

Proteomics startup IP strategy must navigate Thermo/Bruker's dominant MS-instrument portfolios (the hardware is theirs — a dependency), Olink/SomaLogic/Seer and single-molecule players' IP, extensive mass-spec prior art, the DYNAMIC-RANGE and sensitivity challenges (the central proteomics problem), the affinity-vs-MS-vs-single-molecule platform competition, the clinical-validation and reproducibility realities, and a landscape where (for startups) sample prep/dynamic range, affinity reagents, single-molecule sequencing, acquisition, and bioinformatics are the durable assets (the MS hardware usually is NOT); understand that core MS instruments belong to the big vendors, so a startup's durable IP is in dynamic-range compression, affinity binders/readout, single-molecule protein sequencing, and analysis, and that dynamic range/depth, sensitivity, multiplexing, and clinical validation matter as much as patents; identify whitespace in dynamic range, single-molecule sequencing, and affinity. PROTEOMICS STARTUP IP STRATEGY: MS HARDWARE BELONGS TO THERMO/BRUKER — BUILD IP IN SAMPLE PREP, AFFINITY, SINGLE-MOLECULE, AND ANALYSIS: startups generally can't out-patent the instrument vendors, so patent dynamic-range/sample prep, affinity reagents/readout, single-molecule sequencing, acquisition, and bioinformatics — and either ride the MS platforms or go non-MS; DYNAMIC-RANGE COMPRESSION IS THE CENTRAL PROBLEM AND HIGH-VALUE WHITESPACE: seeing low-abundance plasma proteins across ~10 orders is the key challenge — nanoparticle-corona/enrichment methods (Seer) that compress dynamic range are highly valuable; AFFINITY (NON-MS) PROTEOMICS SIDESTEPS MS LIMITS: PEA (Olink) and aptamers (SomaLogic) offer high multiplexing/sensitivity with sequencing/qPCR readout — binder + readout IP is a major, distinct platform; SINGLE-MOLECULE PROTEIN SEQUENCING IS THE FRONTIER (NGS-FOR-PROTEINS): counting individual protein molecules (Nautilus/Quantum-Si) could transform proteomics — emerging, high-value composition/method IP; ACQUISITION/QUANTIFICATION (DIA/TMT) ARE DEFENSIBLE METHOD IP: comprehensive, reproducible acquisition and accurate quantification are valuable; BIOINFORMATICS DIFFERENTIATES AND COMPOUNDS VALUE: peptide/protein ID, quantification, and biomarker analysis (software/trade-secret + patents) add defensible value; CLINICAL VALIDATION AND REPRODUCIBILITY GATE THE MARKET: proteomic biomarkers need rigorous validation and reproducibility — data matters as much as patents; WHEN TO PATENT: NOVEL SAMPLE-PREP/PLATFORM/METHOD WITH MEASURED PERFORMANCE: file once a method shows measured results (proteins detected/depth + dynamic range covered + sensitivity (low-abundance) + multiplexing + throughput + reproducibility (CV) + quantification accuracy) vs. standard-MS/affinity baselines — measured depth/dynamic range, sensitivity, and reproducibility are the critical proteomics IP metrics; KEY FTO CHECKLIST: Thermo Orbitrap high-resolution MS; Bruker timsTOF ion-mobility; SCIEX/Waters MS (instrument FTO/dependency); Seer Proteograph nanoparticle protein-corona dynamic-range; Olink PEA antibody-DNA affinity; SomaLogic SomaScan aptamer; Nautilus/Quantum-Si single-molecule next-gen protein sequencing; MS analyzer resolution/sensitivity/depth; ion mobility; sample prep digestion/depletion/PTM enrichment; dynamic-range compression/low-abundance; affinity binder (antibody/aptamer) + sequencing/qPCR readout; single-molecule fluorescent/nanopore/degradation protein sequencing; data-independent acquisition DIA; quantification TMT/iTRAQ/label-free; PTM phospho/glyco; proteomics bioinformatics/ID/FDR; mass-spec prior art.